Ping Chen

US Patent:

6350145, Feb 26, 2002

Filed:

Jan 5, 2000

Appl. No.:

09/477670

Inventors:

Ping Chen - Mundelein IL
Takashi Iida - Anjo, JP

Assignee:

Japan Solderless Terminal Mfg. Co., Ltd. - Osaka-fu

International Classification:

H01R 424

US Classification:

439422, 439877

Abstract:

An FPC crimp terminal comprising a bottom plate being formed from a flat plate and a fixing part rising from an edge of the bottom plate, said FPC crimp terminal being formed in such a way that when a core or a lead wire is brought into direct contact with a conductor of an FPC, the fixing part is made to pierce the FPC from its back or front and the top end of the fixing part coming out of the FPC is bent towards the bottom plate, the core or the lead wire and the FPC will be pinched between the top end of the fixing part and the bottom plate. As the fixing part is used to effect the piercing process and the connecting process at the same time, the FPC crimp terminal can be compactified and the work efficiency can be enhanced through reduction in the number of processes.

US Patent:

6379199, Apr 30, 2002

Filed:

Sep 9, 1999

Appl. No.:

09/392582

Inventors:

Ping Chen - Mundelein IL

Assignee:

Japan Solderless Terminal Mfg. Co., Ltd. - Osaka

International Classification:

H01R 1122

US Classification:

439852, 439451

Abstract:

A female terminal for a connector wherein a leaf spring is provided inside the terminal proper. The front half of the terminal proper is provided with a bottom wall, side walls rising from both ends, in the direction of width, of the bottom wall, an outer upper wall and an inner upper wall extending from the upper edges of side walls to the upper edges of the opposing side walls. A leaf spring is formed by separating said rear inner upper wall from said side walls, with the rear end of said rear inner upper wall being left intact. A bead with a curved section is formed on the leaf spring to increase the flexural rigidity. The female terminal can be compactified, and a sufficient contacting force can be provided reliably. The contacting part of the leaf spring can be shifted forward. The developed shape can be made smaller.

US Patent:

20130123237, May 16, 2013

Filed:

Feb 23, 2012

Appl. No.:

13/812536

Inventors:

Rajan Anand - Fanwood NJ, US
James M. Apgar - Highland Park NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Lin Chu - Scotch Plains NJ, US
Vincent J. Colandrea - North Brunswick NJ, US
Guizhen Dong - Dayton NJ, US
James F. Dropinski - Colts Neck NJ, US
Danqing Feng - Green Brook NJ, US
Jacqueline D. Hicks - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Alexander J. Kim - Morganville NJ, US
Kenneth J. Leavitt - Plainsboro NJ, US
Bing Li - Towaco NJ, US
Xiaoxia Qian - New York NY, US
Iyassu Sebhat - Jersey City NJ, US
Lan Wei - Berkeley Heights NJ, US
Robert R. Wilkening - Maplewood NJ, US
Zhicai Wu - Montvale NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/5377
A61K 31/437
A61K 31/4985
A61K 31/351
A61K 31/397
A61K 31/4412
C07D 471/04
A61K 31/496

US Classification:

51421021, 546118, 514303, 544362, 51425304, 544127, 5142342

Abstract:

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

US Patent:

20130203786, Aug 8, 2013

Filed:

May 16, 2011

Appl. No.:

13/643121

Inventors:

Jacqueline D. Hicks - Scotch Plains NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Xiaoxia Qian - New York NY, US
Robert R. Wilkening - Maplewood NJ, US

International Classification:

C07D 487/04
A61K 31/506
A61K 45/06
A61K 31/519
A61K 31/437
A61K 31/4162
A61K 31/4439

US Classification:

5142641, 5483565, 514407, 514275, 544331, 5462757, 514338, 544280, 5142651, 514303, 546119, 544279

Abstract:

The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20140080884, Mar 20, 2014

Filed:

Jun 25, 2012

Appl. No.:

14/118998

Inventors:

Itzia Arroyo - Union NJ, US
Davida Krueger - Brooklyn NY, US
Ping Chen - Edison NJ, US
Aaron Moment - Middletown NJ, US
Tesfaye Biftu - Freehold NJ, US
Faye Sheen - Hoddesdon, GB
Yanfeng Zhang - Panan, Zhejiang, CN

Assignee:

Merck Sharp & Dohme Ltd. - Hoddesdon, Hertfordshire
Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04

US Classification:

514407, 5483605

Abstract:

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

US Patent:

57505497, May 12, 1998

Filed:

Oct 15, 1996

Appl. No.:

8/730277

Inventors:

Charles G. Caldwell - Scotch Plains NJ
Ping Chen - Old Bridge NJ
Philippe L. Durette - New Providence NJ
Paul Finke - Milltown NJ
Jeffrey Hale - Westfield NJ
Edward Holson - New York NY
Ihor Kopka - Millburn NJ
Malcolm MacCoss - Freehold NJ
Laura Meurer - Scotch Plains NJ
Sander G. Mills - Woodbridge NJ
Albert Robichaud - Stirling NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3141
C07D25704
C07D27110

US Classification:

514364

Abstract:

The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R. sup. 3, R. sup. 6, R. sup. 7, R. sup. 8, R. sup. 11, R. sup. 12, R. sup. 13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

US Patent:

61742082, Jan 16, 2001

Filed:

Jul 7, 1999

Appl. No.:

9/348393

Inventors:

Ping Chen - Mundelein IL

Assignee:

Japan Solderless Terminal Mfg. Co., Ltd. - Osaka

International Classification:

H01R 1122

US Classification:

439852

Abstract:

A female terminal for a connector comprising a terminal body that is fixed by a retainer of a housing, a leaf spring that extends forward in the terminal body, and a stabilizer that is fixed by a lance of the housing. At the root end of the leaf spring, a round part that bends lengthwise into an approximately circular arc is formed. A bead having a curved section to increase flexural rigidity of the leaf spring is formed ahead of the round part on the top end side. A stabilizer having a face directed in the width direction is erected in the height direction from the top end of the terminal body.

US Patent:

20230018413, Jan 19, 2023

Filed:

Aug 3, 2020

Appl. No.:

17/632065

Inventors:

- Rahway NJ, US
Ping Chen - Edison NJ, US
Dane James Clausen - Rahway NJ, US
Jinsong Hao - Belle Mead NJ, US
Dipannita Kalyani - Union NJ, US
Michael T. Rudd - Collegeville PA, US
Shawn P. Walsh - Bridgewater NJ, US
Lan Wei - Berkeley Heights NJ, US
Dexi Yang - Livingston NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 403/04
C07D 207/14
C07D 401/04
C07D 471/04
C07D 417/04
C07D 413/10
C07D 417/14
C07D 413/04
C07D 409/04
C07D 405/04
C07D 498/04
C07D 491/048

Abstract:

The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.